AbbVie gets FDA approval for antibiotic treatment Emblaveo

AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo.

The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with metronidazole for patients 18 years and older who have limited or no alternative